Relmada Therapeutics (RLMD) Operating Income (2012 - 2026)
Relmada Therapeutics (RLMD) reported Operating Income of -$19.5 million for Q1 2026, down 6.82% year-over-year from -$20.9 million in Q1 2025, and up 4.29% quarter-over-quarter from -$20.3 million in Q4 2025.
Relmada Therapeutics (RLMD) Operating Income (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Operating Income data on file, last reported at -$19.5 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$19.5 million, down 6.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$60.3 million (up 23.73% YoY), and the FY2025 annual result was -$59.1 million, up 29.55% from the prior year.
- Operating Income rose to -$19.5 million in Q1 2026 per RLMD's latest filing, from -$20.3 million in the prior quarter.
- Over five years, Operating Income peaked at -$10.2 million in Q2 2025 and troughed at -$45.5 million in Q2 2022.
- A 5-year average of -$25.1 million and a median of -$23.0 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income sank 71.99% in 2022, then surged 55.12% in 2025.
- A 5-year view of Operating Income shows it stood at -$38.7 million in 2022, then surged by 30.68% to -$26.8 million in 2023, then advanced by 28.9% to -$19.1 million in 2024, then dropped by 6.59% to -$20.3 million in 2025, then climbed by 4.29% to -$19.5 million in 2026.
- Business Quant data shows RLMD's Operating Income at -$19.5 million in Q1 2026, -$20.3 million in Q4 2025, and -$10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -19.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.46 Mn |
| Dec 31, 2025 | -20.33 Mn |
| Sep 30, 2025 | -10.33 Mn |
| Jun 30, 2025 | -10.22 Mn |
| Mar 31, 2025 | -18.22 Mn |
| Dec 31, 2024 | -19.08 Mn |
| Sep 30, 2024 | -23.01 Mn |
| Jun 30, 2024 | -18.82 Mn |
| Mar 31, 2024 | -22.99 Mn |
| Dec 31, 2023 | -26.83 Mn |
| Sep 30, 2023 | -22.69 Mn |
| Jun 30, 2023 | -26.03 Mn |
| Mar 31, 2023 | -28.15 Mn |
| Dec 31, 2022 | -38.70 Mn |
| Sep 30, 2022 | -38.74 Mn |
| Jun 30, 2022 | -45.51 Mn |
| Mar 31, 2022 | -38.30 Mn |
| Dec 31, 2021 | -34.18 Mn |
| Sep 30, 2021 | -42.65 Mn |
| Jun 30, 2021 | -26.46 Mn |